VBVP indicates vinblastine, bleomycin, etoposide, prednisone; VAMP, vinblastine, doxorubicin, methotrexate, prednisone; COPP/ABV, cyclophosphamide, vincristine, procarbazine, prednisone, doxorubicin, bleomycin, vinblastine; DBVE, doxorubicin, bleomycin, vincristine and etoposide; OEPA, vincristine, etoposide, prednisone, doxorubicin; OPPA, vincristine, prednisone, procarbazine, doxorubicin; ABVE-PC, doxorubicin, bleomycin, vincristine, etoposide, prednisone, cyclophosphamide; BEACOPP, bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, prednisone, procarbazine; DECA, dexamethasone, etoposide, cisplatin, cytarabine; SFOP, French Pediatric Oncology Society; CCG, Children's Cancer Study Group; COG, Children's Oncology Group; GPOH, German Society of Pediatric Oncology and Hematology; POG, Pediatric Oncology Group; IF, involved field; RER, rapid early responder; and SER, slow early responder.

* Adverse features: hilar disease, bulk, ≥4 nodal regions, mediastinal bulk.